Skip to Content
Search Menu

RWD for mRCC: Cabozantinib + Nivolumab Shows Comparable Results to CheckMate 9ER

Cabozantinib + Nivolumab redefined first-line treatment in mRCC after showing significant benefit over sunitinib in the phase III CheckMate 9ER study. At ASCO GU, Martin Zarba presents new real-world data exploring how these results translate into clinical practice.
Martin Zarba

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Fernando De Moura

ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

/ Fernando de Moura
ASCOGU26Prostate cancer Play the Video 4:11

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Kidney cancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Kidney cancer

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Kidney cancer
Sylvie Negrier

Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

/ Sylvie Negrier
ASCOGU25Kidney cancer Play the Video 04:15

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
Bladder cancerESMO24Kidney cancerProstate cancer

Rechallenge of IO/TKI in Second-Line After IO/TKI in First-Line Will Not Add Any Benefits

/ Sofie Pohl
Kidney cancer
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
Bladder cancerESMO24Kidney cancerProstate cancer Play the Video 4:25
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Kidney cancer Play the Video 04:33
Back to top